The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Brain implants, made from small clusters of brain cells, could help restore neural pathways damaged by Parkinson’s disease.

What the Trained Eye Cannot See: Detecting Movement Defects in Early Stage Parkinson's Disease Aug. 15, 2024 — Using machine learning to analyze video recordings of individuals performing simple ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

He was admitted to an overseas hospital, where a precordial systolic murmur was heard, and was evacuated with a diagnosis of interventricular septal defect and bundle-branch block. Examination ...

Parkinson's disease is a progressive disorder that develops when the brain cells that produce dopamine (a chemical involved in movement) stop working or die. When this happens, symptoms like slowed ...

Paraquat has drawn scrutiny for its possible links to Parkinson’s disease. It’s one of the most widely used pesticides in the United States.

This review provides insights into the pathophysiology of Parkinson’s disease, highlighting the mechanisms of neurodegeneration, the role of alpha-synuclein, and the disruption of dopaminergic ...

"By bringing these exciting new treatments earlier in the disease pathway, we will continue to see more patients being cured of muscle invasive bladder cancer." Bladder cancer is the ninth most ...

Over an average follow-up period of 14.24 years, 810 participants were subsequently diagnosed with Parkinson's disease. The analysis revealed a 57% increased risk of Parkinson's for every 10 ...